mk-0616
merck
['cardio']
results from efficacy and safety of the oral pcsk9 inhibitor, mk-0616, a macrocyclic peptide, in the treatment of hypercholesterolemia: a phase 2b randomized placebo-controlled clinical trial presented at #acc23 #wccardio by christie m. ballantyne 
Cardiologist; Researcher; PhD of Cardiology; Young Ambassador of ESC; ESCI Young Research Councilor; Young Community Member of ACCA; Young Fellow of the EAS;